Results (2822)
A Real-world, Prospective, Observational Study of Prolia® (20180401)
China
EU PAS number:
EUPAS37579
First published:
16/05/2024
StudyOngoing
A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® (Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers (20130193)
Austria
Finland
Norway
Sweden
United States
EU PAS number:
EUPAS15128
First published:
16/05/2024
StudyOngoing
Pharmacovigilance In Juvenile Idiopathic Arthritis Patients Treated With Biologic Agents And/Or Methotrexate. A Pediatric Rheumatology International Trials Organisation (PRINTO)/Pediatric Rheumatology European Society (PRES) Registry (Pharmachild JIA registry)
Albania
Argentina
Australia
Austria
Belgium
Bosnia and Herzegovina
Brazil
Bulgaria
Chile
China
Colombia
Costa Rica
Croatia
Denmark
Egypt
El Salvador
Estonia
Finland
France
Georgia
Germany
Greece
Hungary
India
Iraq
Israel
Italy
Latvia
Libyan Arab Jamahiriya
Lithuania
Mexico
Montenegro
Netherlands
New Zealand
Norway
Oman
Paraguay
Peru
Poland
Portugal
Romania
Russian Federation
Saudi Arabia
Serbia
Slovakia
Slovenia
South Africa
Spain
Sweden
Switzerland
Türkiye
United Arab Emirates
United Kingdom
Venezuela, Bolivarian Republic of
EU PAS number:
EUPAS1974
First published:
15/05/2024
StudyOngoing
Moderna mRNA-1273 Observational Pregnancy Outcome Study (COVID-19)
Canada
United States
EU PAS number:
EUPAS41463
First published:
15/05/2024
StudyOngoing
mRNA-1273-P920, Post-marketing safety of elasomeran/davesomeran and andusomeran vaccines in the United States
United States
EU PAS number:
EUPAS106694
First published:
15/05/2024
StudyOngoing
mRNA-1273-P911: Long-term Outcomes of Myocarditis Following Administration of SPIKEVAX (COVID-19 Vaccine mRNA)
United States
EU PAS number:
EUPAS107256
First published:
15/05/2024
StudyOngoing
Post-Marketing Safety of SARS-CoV-2 mRNA-1273 Vaccine in the US: Active Surveillance, Signal Refinement and Self-Controlled Risk Interval (SCRI) Signal Evaluation in HealthVerity (COVID-19)
Canada
Finland
Germany
Italy
United States
EU PAS number:
EUPAS41392
First published:
15/05/2024
StudyOngoing
A multicenter evaluation of the treatment persistence of advanced therapies (Biological disease-modifying agents and Targeted synthetic Disease Modifying Anti-Rheumatic Drugs) in the treatment of rheumatoid arthritis (RA): A Real World Evidence (RWE) study from India
India
EU PAS number:
EUPAS103727
First published:
15/05/2024
StudyPlanned
An Immuno-Dermatological disease registry to understand the burden of Atopic dermatitis (AD), Alopecia areata (AA), and Vitiligo in Indian Patients
India
EU PAS number:
EUPAS48566
First published:
15/05/2024
StudyOngoing
A Longitudinal, Retrospective, Multi-centre Observational Study to Evaluate Effectiveness, Persistence, Treatment Patterns and Safety of Australian Patients Receiving Early Access to Tofacitinib
Australia
EU PAS number:
EUPAS41439
First published:
15/05/2024
StudyOngoing
Safety and Effectiveness of MVA-BN vaccination against MPXV infection in at-risk individuals in Germany (SEMVAc) (DRKS ID: DRKS00029638 (SEMVAc))
Germany
EU PAS number:
EUPAS50093
First published:
15/05/2024
StudyPlanned
Use and Safety of Paxlovid Among Patients with Moderate or Severe Hepatic or Renal Impairment
France
Spain
United Kingdom
EU PAS number:
EUPAS50123
First published:
15/05/2024
StudyOngoing
A Post-authorization Safety Study to Evaluate the Safety of Multiple Myeloma Patients Treated with Ciltacabtagene Autoleucel
Austria
Brazil
Germany
EU PAS number:
EUPAS49370
First published:
14/05/2024
StudyPlanned
A Non-Interventional Post-Authorization Safety Study (PASS) for Active Safety Surveillance of Recipients of the Pfizer-BioNTech COVID-19 mRNA vaccine in the EU
Germany
Italy
Spain
EU PAS number:
EUPAS41302
First published:
14/05/2024
StudyFinalised
DARWIN EU® Characterization of patients with chronic hepatitis B and C
Estonia
France
Germany
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS107650
First published:
13/05/2024
StudyFinalised
DARWIN EU® Natural history of dermatomyositis (DM) and polymyositis (PM) in adults and paediatric populations
Estonia
France
Germany
Spain
United Kingdom
EU PAS number:
EUPAS107454
First published:
13/05/2024
StudyFinalised
DARWIN EU® Treatment patterns of drugs used in adult and paediatric population with systemic lupus erythematosus
France
Germany
Spain
United Kingdom
EU PAS number:
EUPAS106436
First published:
13/05/2024
StudyFinalised
DARWIN EU® Drug utilisation study of medicines with prokinetic properties in children and adults diagnosed with gastroparesis
Belgium
France
Germany
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS106798
First published:
13/05/2024
StudyFinalised
DARWIN EU® Use of take-home naloxone for opioid overdose treatment
Belgium
Germany
Spain
United Kingdom
EU PAS number:
EUPAS105644
First published:
13/05/2024
StudyFinalised
DARWIN EU® Age specific incidence rates of RSV related disease in Europe
Estonia
France
Germany
Spain
United Kingdom
EU PAS number:
EUPAS107708
First published:
13/05/2024
StudyFinalised
DARWIN EU® Drug utilization study of prescription opioids
Belgium
Estonia
Finland
France
Germany
Netherlands
Spain
EU PAS number:
EUPAS105641
First published:
13/05/2024
StudyFinalised
DARWIN EU® Multiple myeloma: patient characterisation, treatments and survival in the period 2012-2022
Estonia
Finland
France
Germany
Netherlands
Spain
EU PAS number:
EUPAS105033
First published:
13/05/2024
StudyFinalised
DARWIN EU® - Background rates of serious adverse events to contextualise safety assessments in clinical trials and non-interventional studies in adolescent and adult patients with severe asthma
Estonia
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS103936
First published:
13/05/2024
StudyFinalised
DARWIN EU® - Drug utilisation study on medicinal use of Pelargonii radix
Belgium
Germany
EU PAS number:
EUPAS1000000150
First published:
13/05/2024
StudyOngoing
A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources (COVID-19)
Italy
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS43556
First published:
13/05/2024
StudyOngoing
A retrospective observational chart review study to evaluate the clinical effectiveness of treatment with zanamivir 10 mg/ml solution for infusion in a cohort of intensive care unit-treated (ICU) patients with complicated influenza infection (208165)
Netherlands
United Kingdom
EU PAS number:
EUPAS37605
First published:
13/05/2024
StudyOngoing
EVENITY® Risk Minimisation Materials Effectiveness Measurement in Australia (20220120)
Australia
EU PAS number:
EUPAS104308
First published:
13/05/2024
StudyFinalised
A MULTICENTER, MULTICOUNTRY, POSTMARKETING ACTIVE SURVEILLANCE TALIGLUCERASE ALFA REGISTRY IN PATIENTS WITH GAUCHER DISEASE
Albania
Israel
Türkiye
United States
EU PAS number:
EUPAS4721
First published:
13/05/2024
StudyOngoing
A Retrospective Chart-Review Study to Evaluate the Safety, Effectiveness and Dosing of Dalteparin for Treatment of Venous Thromboembolism (VTE) in Neonates
United Kingdom
EU PAS number:
EUPAS42367
First published:
13/05/2024
StudyFinalised
Evaluation of potential off-label use of dabigatran etexilate in Europe
Denmark
France
United Kingdom
EU PAS number:
EUPAS7591
First published:
13/05/2024
StudyFinalised
Post-Authorisation Safety Study of Agomelatine and the Risk of Hospitalisation for Acute Liver Injury
Denmark
Germany
Spain
Sweden
EU PAS number:
EUPAS10446
First published:
13/05/2024
StudyFinalised
Second primary cancers in patients with castration resistant prostate cancer (BOCARP)
Germany
EU PAS number:
EUPAS12665
First published:
13/05/2024
StudyFinalised
A registry-based non-interventional post-authorization safety study to evaluate the long-term safety of dupilumab in children aged ≥6 months to <6 years with moderate-to-severe atopic dermatitis using the PEDISTAD registry: a cohort design
Argentina
Australia
Belgium
Brazil
Canada
China
Colombia
Denmark
France
Greece
Israel
Italy
Japan
Korea, Republic of
Mexico
Netherlands
Norway
Portugal
Russian Federation
Spain
United States
EU PAS number:
EUPAS1000000149
First published:
09/05/2024
StudyPlanned
An observational study of blinatumomab safety and effectiveness, utilisation, and treatment practices (20150136)
Austria
Czechia
Finland
France
Germany
Greece
Italy
Netherlands
Poland
Portugal
Sweden
Switzerland
United Kingdom
EU PAS number:
EUPAS17848
First published:
09/05/2024
StudyOngoing
The Use of Oral Fluoroquinolones in Canada: Drug Utilization Study Update
Canada
EU PAS number:
EUPAS107333
First published:
08/05/2024
StudyOngoing
TAK-577-4005: Estimating Risk of Selected Adverse Events in Patients with Von Willebrand Disease Treated With VEYVONDI® (Vonicog Alfa; Recombinant Von Willebrand Factor)
Austria
Denmark
France
Germany
Netherlands
Norway
Sweden
United Kingdom (Northern Ireland)
EU PAS number:
EUPAS45617
First published:
08/05/2024
StudyFinalised
Population-based retrospective nested case-control study evaluating effectiveness of GARDASIL™ against adult-onset recurrent respiratory papillomatosis in Sweden (V503-088)
Sweden
EU PAS number:
EUPAS48452
First published:
08/05/2024
StudyOngoing
Antiplatelet Therapy during the First Year after Acute Coronary Syndrome in a Contemporary Italian Community of over 5 Million Subjects
Italy
EU PAS number:
EUPAS1000000154
First published:
08/05/2024
StudyFinalised
Population-based retrospective nested case-control study evaluating effectiveness of GARDASIL™ and GARDASIL 9™ against adult-onset recurrent respiratory papillomatosis in Denmark (V503-089)
Denmark
EU PAS number:
EUPAS50458
First published:
08/05/2024
StudyOngoing
Adakveo (crizanlizumab) PRegnancy outcomes Intensive Monitoring (PRIM) (Adakveo (crizanlizumab) PRIM)
Switzerland
EU PAS number:
EUPAS39412
First published:
08/05/2024
StudyOngoing